Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on Sept. 1, 2022, the approval of stock options for 40,800 shares and 28,000 restricted stock units (RSUs) to eight new employees, aimed at incentivizing key talent. The stock options are priced at $5.06, aligning with the common stock's closing price as of August 31, 2022. Each equity award will vest over four years, contingent on continued employment. Additionally, 7,500 RSUs were granted to Johanna Shulman, VP, Program Lead, with specific vesting terms defined. These grants comply with Nasdaq Listing Rule 5635(c)(4).
Karyopharm Therapeutics (KPTI) reported impressive Q2 2022 results with total revenue of $39.7 million, a 76% increase year-over-year. Net product revenue from XPOVIO® reached $29.0 million, up 44% from Q2 2021. Full marketing authorization for NEXPOVIO® was granted by the European Commission for adults with multiple myeloma who had prior therapy. The company updated its 2022 revenue guidance to between $155 million and $165 million. Despite challenges due to COVID-19 and competition, Karyopharm expects to maintain a cash runway into early 2024.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the 2022 Wedbush Pacgrow Healthcare Conference. The virtual event will feature a fireside chat with the company's senior management team on August 9, 2022, at 4:05 p.m. ET. Investors can access the live webcast on Karyopharm's website under the 'Events & Presentations' section, which will be available for replay for 90 days post-event. Karyopharm is known for pioneering novel cancer therapies and its lead compound, XPOVIO (selinexor), is approved in multiple oncology indications.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 26,100 shares and 18,000 restricted stock units (RSUs) to eight new employees, effective July 29, 2022. The stock options have an exercise price of $4.25 and will vest over four years. RSUs will similarly vest over four years, contingent upon the employees’ continued service. This grant is part of Karyopharm's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). Karyopharm focuses on innovative cancer therapies, including its leading product, XPOVIO®.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) will announce its second quarter 2022 financial results on August 4, 2022, at 8:00 a.m. ET. The management team will host a conference call to discuss these results and provide updates on the company. Karyopharm is recognized for its novel cancer therapies, particularly its oral Exportin 1 (XPO1) inhibitor, XPOVIO (selinexor), which has regulatory approvals in various regions. For further details, visit their investor website.
Karyopharm Therapeutics Inc. (KPTI) and the Menarini Group announced the European Commission's full approval for NEXPOVIO® (selinexor) for treating adults with multiple myeloma after at least one prior therapy. This follows a positive opinion from the CHMP in May 2022 and is based on the Phase 3 BOSTON study results, which showed improved patient outcomes. The approval allows for extended use in all EU member states and select countries, addressing a significant medical need as approximately 51,000 new multiple myeloma cases arise annually in Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that the European Commission has granted full Marketing Authorisation for NEXPOVIO® (selinexor) to treat adults with multiple myeloma after at least one prior therapy. This approval follows a positive opinion from the CHMP based on the Phase 3 BOSTON study, demonstrating that the combination of NEXPOVIO with bortezomib and dexamethasone significantly reduces disease progression risk. The indication is effective across all EU member states and other territories. Karyopharm aims to enhance patient access to this treatment.
Karyopharm Therapeutics (KPTI) announced that its investigational drug, eltanexor, received FDA Fast Track designation and European Orphan Medicinal Product designation for the treatment of myelodysplastic syndromes (MDS). This signifies a crucial need for new therapies for patients with relapsed or refractory MDS, which currently lacks approved treatments. About 15,000 and 14,000 individuals in the U.S. and EU, respectively, are projected to be diagnosed with high-risk MDS in 2022. The fast track process aims to expedite drug development, while orphan designation allows for various incentives.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the approval of stock options for 32,600 shares and 22,400 restricted stock units (RSUs) to 11 new employees, effective June 30, 2022. These grants serve as inducements for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options, priced at $4.51, will vest over four years, with 25% vesting after one year and the remainder monthly. RSUs will vest similarly over four years. Each award can be exercised fully if employment ends for 'good reason' or is terminated without 'cause' within the first year after a change in control.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 136,700 shares and 90,700 restricted stock units (RSUs) to 18 newly hired employees as of May 31, 2022. This is part of the Company's 2022 Inducement Stock Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $6.28 per share and will vest over four years. The RSUs will also vest over four years, with 25% vesting annually. These awards incentivize talent acquisition in the competitive pharmaceutical industry.